As of the first quarter of 2026, the European "unicorn" class, private companies valued at over $1 Billion is no longer dominated solely by consumer-facing digital health applications. Instead, the ecosystem has matured into deep-tech enterprises integrating generative artificial intelligence (AI) into the fabric of drug discovery, surgical robotics seeking entry into the lucrative U.S. ambulatory market, and platform-based care delivery models that bridge the gap between hos

As the global healthcare sector approaches the 2026 fiscal year, the capital markets are poised for a definitive structural transformation. Following a tumultuous half-decade characterized by the exuberant highs of the Zero Interest Rate Policy (ZIRP) era and the subsequent liquidity crunch of 2022–2024, the IPO landscape has entered a phase of "Rational Exuberance." This new paradigm is defined not by the speculative fervour that drove the 2020–2021 vintage, but by a discipl

The global healthcare landscape is rapidly converging upon a singular, undeniable crisis point regarding musculoskeletal (MSK) health, creating a definitive "before and after" scenario centered around the year 2026. For decades, MSK disorders, encompassing conditions ranging from non-specific low back pain (LBP) to complex post-surgical rehabilitation, have served as the silent epidemic of the industrialised world. However, as we approach the latter half of the 2020s, the con

The European digital health market is at a pivotal inflection point, with the musculoskeletal (MSK) sector emerging as a primary frontier for innovation and investment. This market is not merely growing; it is undergoing a fundamental transformation, driven by an aging demographic, the increasing prevalence of chronic conditions, and a critical shift towards data-enabled, value-based care. The European Digital MSK market is projected to reach a revenue of US$3.28 Billion by 2

The IPO landscape for HealthTech startups in 2025 is likely to be dynamic, influenced by various factors such as market conditions, company performance and regulatory changes. While it's challenging to predict with certainty which specific companies will go public, the following six HealthTech startups have the potential to be among the IPO candidates: Omada Health, Hinge Health, Sword Health, Doctolib, Aledade, Quantum Health